An interventional study of D Blue Diode Laser and ProSylc Bioactive Glass Powder in Non-Carious Cervical Lesions (NCCLs) and Dentin Hypersensitivity, sponsored by Cukurova University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-15.
Sponsored by Cukurova University · Not applicable, Interventional, and Treatment
The aim of this split-mouth clinical study is to compare the effectiveness of D Blue diode laser application and ProSylc bioactive glass powder application in reducing dentin hypersensitivity in patients with non-carious cervical lesions (NCCLs). Different treatment modalities will be applied within the same participant, and changes in dentin hypersensitivity will be evaluated following treatment. The primary outcome measure will be the reduction in dentin hypersensitivity after the interventions. The findings of this study are expected to contribute to the identification of effective non-invasive treatment approaches for the management of dentin hypersensitivity associated with non-carious cervical lesions.
This split-mouth clinical study was designed to compare the clinical effectiveness of two different non-invasive approaches used in the treatment of dentin hypersensitivity associated with non-carious cervical lesions (NCCLs). Dentin hypersensitivity is a common clinical condition characterized by a short, sharp pain arising from exposed dentin in response to thermal, evaporative, tactile, osmotic, or chemical stimuli. Non-carious cervical lesions play a significant role in the development of dentin hypersensitivity by exposing dentin surfaces to the oral environment.
In this study, the effectiveness of D Blue diode laser application and ProSylc bioactive glass powder application in reducing dentin hypersensitivity will be evaluated. The split-mouth study design will allow each participant to serve as their own control, thereby minimizing interindividual variability. Eligible teeth will be allocated to different treatment groups according to the study protocol, and all interventions will be performed following standardized clinical procedures.
The level of dentin hypersensitivity will be assessed before treatment and at predetermined follow-up intervals using standardized clinical evaluation methods. Based on the collected data, the effects of both treatment modalities on dentin hypersensitivity will be compared, and changes over time will be analyzed. In addition, the clinical applicability and patient tolerance of the interventions will be evaluated.
The findings of this study are expected to contribute to the existing literature regarding the effectiveness of non-invasive treatment methods for dentin hypersensitivity associated with non-carious cervical lesions and to provide evidence-based guidance for clinicians in selecting appropriate treatment approaches.
288 studies on the registry are indexed under Dentin Sensitivity; 46 are open to participants now.
This study's planned enrollment of 30 is below the median of 60 across 279 interventional studies indexed under Dentin Sensitivity.
Browse Dentin Sensitivity studies →Cukurova University is the lead sponsor of 259 studies on the registry; 50 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants who agree to participate in the study and sign the form
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Teeth assigned to this group will receive D Blue diode laser application for the management of dentin hypersensitivity associated with non-carious cervical lesions.
Device: D Blue Diode Laser
Teeth assigned to this group will receive ProSylc bioactive glass powder application for the management of dentin hypersensitivity associated with non-carious cervical lesions.
Device: ProSylc Bioactive Glass Powder
D Blue diode laser application for the treatment of dentin hypersensitivity associated with non-carious cervical lesions.
Also known as: Diode Laser
ProSylc bioactive glass powder application for the treatment of dentin hypersensitivity associated with non-carious cervical lesions.
Also known as: Bioactive Glass Powder
Change in Dentin Hypersensitivity
Dentin hypersensitivity will be assessed using a Visual Analog Scale (VAS) following standardized air stimulus application. The change in VAS scores from baseline to follow-up visits will be evaluated.
Time frame: Baseline, immediately after treatment, 1 week, 1 month, and 3 months
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.